Everist Genomics has launched four companion diagnostics intended to improve early diagnosis, management, and treatment of patients with colorectal cancer.
The tests, which will be available in the US at the end of March, include:
• OncoDefender-MMR, used for prognosis for colorectal cancer patients at all stages of the disease;
• OncoDefender-CRC, designed to identify early-stage colorectal cancer patients likely to benefit from adjuvant chemotherapy;
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
